Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES102 + Toripalimab in Advanced Solid Tumors
NCT04991506Phase 1Completed
- Sponsor
- Elpiscience
- Start
- Oct 2021
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of inbrx-106 in solid tumor (advanced stage) (2 arms), sponsored by Elpiscience. Primary endpoints: Maximum Tolerated Dose, Adverse Events and 1 more. Started Oct 2021; status: completed.
02
Drugs
inbrx-106
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04991506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991506.